ITIF Logo
ITIF Search

Reports & Briefings

November 15, 2024

Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.

November 15, 2024

US-India Subnational Innovation Competitiveness Index

For policymakers to bolster the global competitiveness of their nations and regions, they first must know where they stand. This report benchmarks the 87 regions of India and the United States using 13 commonly available indicators of strength in the knowledge economy, globalization, and innovation capacity.

November 14, 2024

GTIPA Perspectives: The Vital Importance of Digital Inclusivity for Global Economic Growth

Information and communications technology (ICT) is driving global economic growth and economic opportunity. Many countries are taking effective steps to deploy digital infrastructure, enhance citizens’ digital skills and literacy, empower women and disabled citizens to leverage digital tools, and helping small- and medium-sized enterprises take advantage of digital technologies.

October 28, 2024

Evidence to Inform Biopharmaceutical Policy: A Call for Research on the Impact of Public Policies on Investment in Drug Development

The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.

October 23, 2024

Evidence-Based Biopharmaceutical Policymaking: Symposium Report

There is a need for more rigorous evidence and more recent, high-quality data to inform biopharmaceutical policymaking by shedding light on the relationship between pharmaceutical firms’ expectations of financial returns from new drugs and their ability to invest in further R&D to discover future generations of drugs.

October 21, 2024

Go to the Mattresses: It’s Time to Reset U.S.-EU Tech and Trade Relations

In its bid for tech sovereignty, the EU has been aggressively targeting U.S. firms and industries with unfair protectionist policies. This cannot stand. To move forward into a new era of deeper transatlantic trade integration, America must first demand a level playing field.

October 7, 2024

The Conservative Weaponization of Government Against Tech

Some conservatives have grievances with “Big Tech” companies and would marshal the power of government to punish them. But the policy proposals stemming from this conservative “techlash” would have significant costs for consumers, businesses, and the economy.

September 30, 2024

Why Wind and Solar Need Natural Gas: A Realistic Approach to Variability

Wind and solar power will replace consistently dispatchable electricity from fossil fuels with variable and more unpredictable clean energy. Seasonal shifts and annual variations cannot be handled with batteries or other proposed storage solutions like hydrogen. Natural gas will have to bridge the gap for many decades.

September 23, 2024

The Path to Digital Identity in the United States

Digital IDs are a more convenient, secure, and versatile option than physical IDs, but few Americans currently have one. With the right investments and collaboration between federal and state governments, Americans could realize the full potential of digital IDs.

September 16, 2024

China Is Rapidly Becoming a Leading Innovator in Advanced Industries

There may be no more important question for the West’s competitive position in advanced industries than whether China is becoming a rival innovator. While the evidence suggests it hasn’t yet taken the overall lead, it has pulled ahead in certain areas, and in many others Chinese firms will likely equal or surpass Western firms within a decade or so.

Back to Top